| Membrane transporters in drug development Nature reviews Drug discovery 9 (3), 215-236, 2010 | 3608 | 2010 |
| Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities XQ Li, TB Andersson, M Ahlström, L Weidolf Drug metabolism and disposition 32 (8), 821-827, 2004 | 968 | 2004 |
| Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes A Äbelö, TB Andersson, M Antonsson, AK Naudot, I Skånberg, L Weidolf Drug Metabolism and Disposition 28 (8), 966-972, 2000 | 498 | 2000 |
| Pharmacokinetics, metabolism and interactions of acid pump inhibitors: focus on omeprazole, lansoprazole and pantoprazole T Andersson Clinical pharmacokinetics 31, 9-28, 1996 | 473 | 1996 |
| Physiological disturbances in fish living in coastal water polluted with bleached kraft pulp mill effluents T Andersson, L Förlin, J Härdig, Å Larsson Canadian Journal of Fisheries and Aquatic Sciences 45 (9), 1525-1536, 1988 | 453 | 1988 |
| Evaluation of HepaRG cells as an in vitro model for human drug metabolism studies KP Kanebratt, TB Andersson Drug metabolism and disposition 36 (7), 1444-1452, 2008 | 419 | 2008 |
| Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis A Kindmark, A Jawaid, CG Harbron, BJ Barratt, OF Bengtsson, ... The pharmacogenomics journal 8 (3), 186-195, 2008 | 409 | 2008 |
| Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5′-upstream regulatory region A Westlind, L Löfberg, N Tindberg, TB Andersson, M Ingelman-Sundberg Biochemical and biophysical research communications 259 (1), 201-205, 1999 | 396 | 1999 |
| Regulation of the cytochrome P450 enzyme system in fish T Andersson, L Förlin Aquatic Toxicology 24 (1-2), 1-19, 1992 | 377 | 1992 |
| Biology-inspired microphysiological system approaches to solve the prediction dilemma of substance testing U Marx, TB Andersson, A Bahinski, M Beilmann, S Beken, FR Cassee, ... Altex 33 (3), 272, 2016 | 352 | 2016 |
| Amodiaquine clearance and its metabolism ton-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate XQ Li, A Björkman, TB Andersson, M Ridderström, CM Masimirembwa Journal of Pharmacology and Experimental Therapeutics 300 (2), 399-407, 2002 | 340 | 2002 |
| Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism A Westlind-Johnsson, S Malmebo, A Johansson, C Otter, TB Andersson, ... Drug Metabolism and Disposition 31 (6), 755-761, 2003 | 321 | 2003 |
| Identification of human cytochrome P450s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data XQ Li, A Björkman, TB Andersson, LL Gustafsson, CM Masimirembwa European journal of clinical pharmacology 59, 429-442, 2003 | 293 | 2003 |
| The HepaRG cell line: a unique in vitro tool for understanding drug metabolism and toxicology in human TB Andersson, KP Kanebratt, JG Kenna Expert opinion on drug metabolism & toxicology 8 (7), 909-920, 2012 | 271 | 2012 |
| Cloning and tissue distribution of a novel human cytochrome p450 of the CYP3A subfamily, CYP3A43 A Westlind, S Malmebo, I Johansson, C Otter, TB Andersson, ... Biochemical and biophysical research communications 281 (5), 1349-1355, 2001 | 268 | 2001 |
| Differential induction of cytochrome P-450-dependent monooxygenase, epoxide hydrolase, glutathione transferase and UDP glucuronosyl transferase activities in the liver of the … T Andersson, M Pesonen, C Johansson Biochemical pharmacology 34 (18), 3309-3314, 1985 | 257 | 1985 |
| Biology-inspired microphysiological systems to advance patient benefit and animal welfare in drug development U Marx, T Akabane, TB Andersson, E Baker, M Beilmann, S Beken, ... Altex 37 (3), 365, 2020 | 254 | 2020 |
| Functional coupling of human pancreatic islets and liver spheroids on-a-chip: Towards a novel human ex vivo type 2 diabetes model S Bauer, C Wennberg Huldt, KP Kanebratt, I Durieux, D Gunne, ... Scientific reports 7 (1), 14620, 2017 | 253 | 2017 |
| Novel 3D culture systems for studies of human liver function and assessments of the hepatotoxicity of drugs and drug candidates VM Lauschke, DFG Hendriks, CC Bell, TB Andersson, ... Chemical research in toxicology 29 (12), 1936-1955, 2016 | 253 | 2016 |
| HepaRG cells as an in vitro model for evaluation of cytochrome P450 induction in humans KP Kanebratt, TB Andersson Drug metabolism and disposition 36 (1), 137-145, 2008 | 246 | 2008 |
